Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias

11 Apr 2014

Abstract excerpt

Acute and chronic leukemias, including CD34(+) CML cells, demonstrate increased expression of the Wilms tumor gene 1 product (WT1), making WT1 an attractive therapeutic target. However, WT1 is a currently undruggable, intracellular protein. ESKM is a human IgG1 T-cell receptor mimic monoclonal antibody directed to a 9-amino acid sequence of WT1 in the context of cell surface HLA-A*02. ESKM was therapeutically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Renal and related cancers
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24723681
DOI: 10.1182/blood-2014-01-549022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemiasPMID 24723681Read ↗

Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapySemantic proximity Read ↗

The role of the Wilms tumour gene (<i>WT1</i>) in normal and malignant haematopoiesisSemantic proximity Read ↗

The many facets of WT1 in acute myeloid leukemia: clarity remains elusive.Semantic proximity Read ↗

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevanceSemantic proximity Read ↗

Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II AllelesSemantic proximity Read ↗

Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance.Semantic proximity Read ↗

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell functionSemantic proximity Read ↗

Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry.Semantic proximity Read ↗

Upregulation of HOXA3 by isoform‐specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemiaSemantic proximity Read ↗

Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemiaSemantic proximity Read ↗

Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.Semantic proximity Read ↗

Upregulation of HOXA3 by Isoform-Specific Wilms Tumor 1 Drives Chemotherapy Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.